Japan Faces “Worst

News Highlights

A naphtha shortage is expected to have a severe impact on the entire Japanese economy, with bankruptcies projected to surge across almost all industries. Medical institutions, in particular, are facing a critical situation where rising procurement costs for items like injectable drugs mean they “lose money the more they administer them.” Specific figures, such as a 26% increase in bankruptcies within the paint contracting business, highlight the growing economic pressure. This situation is expected to have a significant impact on the management succession and M&A strategies of medical institutions.

Perspective from M&A Medical Editorial Department

The Daily Shincho article depicts the “worst-case scenario” of soaring naphtha prices directly hitting the management of medical institutions, describing the specific hardship of “losing money the more they administer injections.” This is a symbolic expression of the severity of cost increases faced by medical facilities. Rising prices for pharmaceuticals and medical supplies put pressure on the profitability structure of medical institutions, which have a high proportion of fixed costs. Even hospitals that have maintained profitability may soon show signs of deteriorating financial statements, such as a worsening current ratio or consecutive operating losses. In such circumstances, it is crucial for hospitals, not only those facing a lack of successors but also those where current directors feel the limits of continued operation, to begin considering M&A or business succession early. This will be key to maximizing options for negotiating the release of personal joint guarantees by directors and ensuring the continuity of regional healthcare.

Points Raised by This News

• The risk that increased procurement costs for pharmaceuticals and medical supplies will reduce the profitability of medical services themselves.
• The possibility that a deteriorating current ratio and consecutive operating losses on financial statements will serve as early warning signs of management decline.
• Economic pressure from soaring naphtha prices could be a factor prompting hospital managers, beyond those with a lack of successors, to consider business succession and M&A.
• The increasing importance of succession schemes that transfer patient bases and staff employment, rather than closing down, to ensure the sustainability of regional healthcare.

Practical Questions Arising from This News

• If procurement prices for injectable drugs rise, what specific level of cost increase can be anticipated?
• In what timeframe could the situation of “losing money the more they administer” occur?
• Under these circumstances, what kind of terms would be realistic for negotiating M&A or business succession?

If You Feel “Should I Consult?”

If your institution is experiencing a significant increase in procurement costs for pharmaceuticals and medical supplies, and you are starting to feel management pressure that cannot be absorbed by fee schedule revisions alone, this may be a sign to consider M&A or business succession. Particularly if personal joint guarantees from the director remain, consulting with experts while the institution is still sound can create room for negotiation towards their release. To protect regional healthcare, the possibility of continuation through succession should be explored before reaching the option of closure.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as a certified M&A support institution by the Small and Medium Enterprise Agency, on a full success fee basis. Consultations are accepted with strict confidentiality. Free consultations are available here.